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ABSTRACT
Regulation of the elongation phase of RNA poly-
merase II transcription by P-TEFb is a critical
control point for gene expression. The activity of
P-TEFb is regulated, in part, by reversible associa-
tion with one of two HEXIMs and the 7SK snRNP. A
recent proteomics survey revealed that P-TEFb and
the HEXIMs are tightly connected to two pre-
viously-uncharacterized proteins, the methypho-
sphate capping enzyme, MEPCE, and a La-related
protein, LARP7. Glycerol gradient sedimentation
analysis of lysates from cells treated with P-TEFb
inhibitors, suggested that the 7SK snRNP reorga-
nized such that LARP7 and 7SK remained asso-
ciated after P-TEFb and HEXIM1 were released.
Immunodepletion of LARP7 also depleted most of
the 7SK regardless of the presence of P-TEFb,
HEXIM or hnRNP A1 in the complex. Small inter-
fering RNA knockdown of LARP7 in human cells
decreased the steady-state level of 7SK, led to an
initial increase in free P-TEFb and increased Tat
transactivation of the HIV-1 LTR. Knockdown of
LARP7 or 7SK ultimately caused a decrease in total
P-TEFb protein levels. Our studies have identified
LARP7 as a 7SK-binding protein and suggest that
free P-TEFb levels are determined by a balance
between release from the large form and reduction
of total P-TEFb.
INTRODUCTION
The human positive transcription elongation factor b
(P-TEFb), which is composed of Cdk9 and cyclin T1 or
cyclin T2 (1–3), stimulates the elongation phase of
transcription by reversing the eﬀects of negative elonga-
tion factors [for recent reviews see (4,5)]. P-TEFb plays an
important role in the transcription of cellular genes (6),
and is also a key factor for the expression of the human
immunodeﬁciency virus type 1 (HIV-1) genome (7–9).
Previous studies have shown that a complex containing
the 7SK small nuclear RNA (snRNA), a 332-nucleotide
transcript synthesized by RNAPIII (10,11), and the RNA
binding proteins HEXIM1 (12,13) or HEXIM2 (14,15)
can interact with P-TEFb and inhibit its kinase activity
(16). Signal transduction pathways have been implicated
in the general release of P-TEFb from the large form
during cardiac hypertrophy (17,18) and upon treatment of
cells with the diﬀerentiation agent, HMBA (19). Also,
transfection of cells with the HIV transactivator, Tat,
leads to release of P-TEFb from the large form and the
formation of a Tat P–TEFb complex (20). Recent results
from several labs indicate that P-TEFb may play a critical
role during development. Poised polymerases have been
found on most human genes in embryonic stem cells (21)
and on most developmental control genes in Drosophila
(22,23).
Recently, soluble human protein complexes containing
components of the transcription and RNA processing
machineries were analyzed using protein aﬃnity puriﬁca-
tion coupled to mass spectrometry. Thirty-two tagged
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interactions (24). This study revealed that besides its
positive (Brd4) (25,26) and negative (HEXIMs and 7SK
snRNA) regulators, P-TEFb is tightly connected to many
other proteins, including the previously uncharacterized
protein BCDIN3 [Bicoid-interacting 3, homolog
(Drosophila)]. BCDIN3 is a conserved methyltransferase
that has the ability to add a methyl group on the
g-phosphate of 7SK and because of this was renamed
the methyl phosphate capping enzyme, MEPCE (24). The
addition of this unusual mono-methyl cap structure to
RNAPIII-synthesized snRNAs, such as 7SK, was pre-
viously shown to occur post-transcriptionally and to be
important for protecting the RNA from exonucleolytic
degradation (27). Indeed, it has been shown that the cap
structure enhances the stability of U6 and 7SK snRNAs
and that uncapped U6 snRNA is rapidly degraded (28).
In support for a role of capping by MEPCE on 7SK
stability, silencing of MEPCE was shown to decrease the
steady-state level of cellular 7SK in vivo (24). Here we
follow-up on another previously uncharacterized protein,
LARP7, which was discovered to be connected with
P-TEFb and HEXIM proteins (24).
MATERIALS AND METHODS
Affinity purification ofahuman LARP7-containing
complex
The cDNA encoding human LARP7 (Invitrogen; acces-
sion number BC066945) was cloned into the mammalian
expression vector pMZI (29) carrying a tandem aﬃnity
puriﬁcation (TAP) tag at its C-terminus and a stable
human embryonic kidney (HEK) cell line EcR-293
(derived from HEK 293) carrying this construct was
produced (30). The conditions for expression, aﬃnity
puriﬁcation, mass spectrometry identiﬁcation of proteins
and gel ﬁltration chromatography were as previously
described (24).
Generationof affinity purified LARP7 antibodies
C-terminally His-tagged recombinant LARP7 was
expressed in Escherichia coli BL21 CodonPlus (DE3)
RIL cells (Stratagene) from a LARP7 containing pET23a
expression vector (Novagene). Cells were induced over-
night with 0.1mM isopropyl 1-thio-b-D-galactopyranoside
at 188C. Puriﬁcation on Ni-NTA resin and mono S was
carried out as previously described for the puriﬁcation of
HEXIM proteins (14). One fraction from the Mono S
elution containing predominately a 38kDa, C-terminal
proteolysis product of LARP7 was used as an antigen
to generate sheep antibodies (Elmira Biologicals). The
LARP7 antibodies were aﬃnity puriﬁed from the crude
serum by the method previously described for puriﬁcation
of HEXIM2 antibodies (14).
Glycerol gradientanalysis
HeLa cells were grown to 90% conﬂuence in two T-150
ﬂasks. Cells were then treated for 1h with 500nM
Flavopiridol or mock-treated with carrier (0.004%
DMSO). Cells were harvested, lysed with a buﬀer
containing 150mM NaCl, and subjected to glycerol
gradient fractionation as previously described (31).
Gradient fractions were resolved by 9% SDS–PAGE
followed by transfer to 0.45mm nitrocellulose membranes.
The antibodies used for western blotting were: sheep anti-
cyclin T1 (ab27963; Abcam), rabbit anti-Cdk9 (sc-8338;
Santa Cruz Biotechnology), aﬃnity-puriﬁed sheep anti-
HEXIM1 (Abcam), rabbit anti-MEPCE (24) and aﬃnity-
puriﬁed sheep anti-LARP7. Western blots were incubated
with the appropriate horseradish peroxidase-conjugated
secondary antibody (Sigma) and then treated with
Super Signal Dura West Extended Duration Substrate
(Pierce). Blots were imaged using a cooled charge-coupled
camera (UVP).
Immunoprecipitation
Glycerol gradient analyses of Flavopiridol-treated or
untreated HeLa cells were performed as described
before. fractions 8–11, which contain the majority of
LARP7 and the large form of P-TEFb, were pooled. To
immunoprecipitate LARP7, aﬃnity puriﬁed LARP7 anti-
bodies were covalently attached to Actigel ALD beads
(Sterogene) according to the manufacturer’s instructions.
Glycerol gradient pools were pre-cleared with beads
alone at 48C for 1h. The ﬂow through from the pre-
clearing was then added to beads bound with aﬃnity
puriﬁed LARP7 or beads alone and rotated for 1h at 48C.
The beads were washed with IP buﬀer [10mM
HEPES, 2mM MgCl2, 10mM KCl, 0.1% NP-40,
0.5mM EDTA, 150mM NaCl, 0.1% PMSF, and 1 unit/
ml Complete EDTA Free Protease Inhibitor Cocktail
(Roche)]. Trizol reagent (Invitrogen) was then added
directly to the beads to extract immunoprecipitated
7SK according to the manufacturer’s protocol. Extracted
RNA was resolved on a denaturing 6% TBE acrylamide
RNA gel, ethidium bromide (EtBr) stained, and
visualized using a cooled charge-coupled camera (UVP).
RNAs were transferred from the acrylamide gels to 0.2mm
Nytran N nylon membranes (Whatman) and then
blocked for 1h at 658C in Ultrahybe Hybridization
Buﬀer (Ambion). Radioactively tagged RNA oligos for
U2, U6 or 7SK (31) were then added to the hybridization
buﬀer and incubated overnight at 658C. Blots were
visualized using a Packard InstantImager and then
exposed to ﬁlm.
Co-immunoprecipitation of LARP7 associated proteins
was similar; however, protein G Sepharose beads (Sigma)
were used as the immunoprecipitation substrate to obtain
better yields of LARP7 which was bound tightly by the
antibodies. After immunoprecipitation, beads were resus-
pended in SDS loading buﬀer and boiled for 10min at
1008C to release the bound protein from the beads. The
immunoprecipitated proteins were resolved, blotted and
probed with LARP7, Cdk9, MEPCE, and HEXIM1
antibodies as described before.
For co-immunoprecipitation from DRB-treated cells,
cells were treated with 100mM DRB for 1h, and whole cell
extracts were prepared using the same lysis buﬀer as was
2220 Nucleic Acids Research, 2008, Vol. 36, No. 7used for glycerol gradient analysis. Co-immunoprecipita-
tions were carried out as described before.
Electrophoretic mobility shiftassayand 7SK invitro
transcription
The mobility shift assay was carried out as previously
described for the binding of HEXIM1 to RNA (31). In
short, 0, 10 or 30ng of recombinant LARP7 was
combined in binding buﬀer (25mM HEPES pH 7.6,
15% glycerol, 60mM KCl, 0.1mM EDTA, 5mM DTT,
0.01% NP-40, 100ng/ml BSA, 200ng/rxn yeast tRNA)
with 1ng a-
32P-UTP labeled 7SK for 20min at room
temperature and then resolved on a 4% native Tris
polyacrylamide gel. 7SK was transcribed in vitro from a
cut pCR2.1 (Invitrogen) template driven by a T7 pro-
moter using T7 polymerase (Stratagene) in the presence of
a-
32P-UTP.
Small interfering RNA knockdown and luciferase assay
LARP7-speciﬁc small interfering RNA (siRNA) (custom
synthesized by Integrated DNA Technologies, target
sequence: 50-ACAAGCGAGUAAACAUAUA-30),
MEPCE-speciﬁc siRNA (24) and control siRNA
(Dharmacon siCONTROL Non-targeting pool), 7SK-
speciﬁc siRNA (custom synthesized by Integrated DNA
Technologies, targeting nucleotides 220-238) were trans-
fected in 50%-conﬂuent HEK 293 cells, TZM-bl cells
or HeLa cells using Lipofectamine 2000 (Invitrogen) at
a ﬁnal siRNA concentration of 100nM. TZM-bl cells,
HeLa-cell derivatives that are stably transduced with a
LTR-driven ﬁreﬂy luciferase cassette, were obtained from
the NIH AIDS Reference and Reagent Program. Cells
were transfected with the siRNAs twice at a 24h interval.
At various time intervals post-transfection, cells were
lysed and LARP7 expression levels were monitored by
western blotting. RNA blot analysis of total RNAs
from LARP7-TAP eluate, HEK 293 cells mock-treated
or treated with siRNA were carried out as previously
described.
For luciferase assays, HEK 293 cells or TZM-bl cells
were ﬁrst mock-transfected or transfected with the
control, MEPCE, LARP7 or double (MEPCE and
LARP7) siRNAs as indicated before. Following an
incubation of 5h, the media was changed and a second
siRNA transfection was performed 24h later using similar
conditions. After an incubation of 3h, cells were
co-transfected with 0.5mg of the luciferase reporter
construct and 0.1mg of the Tat expressing plasmid or
control plasmid. The plasmid encoding Tat (SV CMV
Tat), the control plasmid (SV CMVexPA), as well as the
LTR-driven ﬁreﬂy luciferase plasmid (pGL2-43-LTR-luc)
were described previously (32). Transfected cells were
collected 24h post-ﬁnal transfection and lysed using the
luciferase assay system buﬀer (Promega). The protein
concentration in cell lysates was determined using the
Bio-Rad Protein Assay kit (Bio-Rad Laboratories).
The luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega).
RESULTS
LARP7 isassociated withP-TEFb, HEXIM1/2,
MEPCEand 7SK RNA
In a recent study (24), a protein interaction network of
human transcription and RNA processing machinery was
constructed. P-TEFb was found to be associated with its
negative regulators (HEXIMs and 7SK snRNA), the 7SK
capping enzyme (MEPCE), and among other proteins, a
previously uncharacterized protein, LARP7. A bioinfor-
matics analysis revealed that LARP7 is a member of a
family of about a dozen La related proteins generated
from seven human genes. Of all the family members
LARP7 is the most closely related to La. In their amino
terminal halves, both La and LARP7 contain the La
domain and an associated RNA recognition motif
(RRM1) (Figure 1A). A recent structure determination
using a co-crystal of La and an RNA oligo (33) strongly
suggests that both the La domain and RRM1 are involved
in the interaction of La with the 30 end of newly
synthesized RNAPIII transcripts (34,35). Both proteins
also contain a second RRM (RRM3) in their carboxyl
terminal half (Figure 1A). Previous studies have shown
that the La protein is a multifunctional protein that binds
to and plays key roles in RNA metabolism (35,36).
In the study presented here, we further characterize the
association of LARP7 with the 7SK snRNP and deter-
mine the functional consequences of knocking down
LARP7 in human cells.
To better identify the interaction partners of LARP7,
a human HEK 293 cell line was stably transfected with
a construct that expressed C-terminally TAP-tagged
LARP7at about the same level as the endogenous
LARP7. The proteins found in aﬃnity puriﬁed LARP7
complexes were identiﬁed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) after separation
of the proteins on an SDS gel. Figure 1B shows the
composition of the TAP-tagged LARP7 eluate. Proteins
that have been either identiﬁed in a control eluate
prepared from the non-induced cell extract or represent
interactions that had Interaction Reliability scores below a
stringent threshold (24) were not listed. RNA extracted
from the TAP-tagged LARP7 eluate was subjected to
northern analysis. Consistent with the results obtained
earlier with MEPCE (24), 7SK and U6 snRNAs, but not
U2 snRNA were pulled down with LARP7 (Figure 1C).
As we have previously shown for the MEPCE-TAP eluate
(24), both 7SK and U6 RNAs were found partially
degraded when compared to their respective cellular
counterpart isolated from total cell RNA. This is due to
extensive incubations of the RNPs in crude extracts. Also
relatively less U6 came down with LARP7 compared to
that brought down by MEPCE suggesting that LARP7
might preferentially associate with 7SK or that MEPCE
might preferentially associate with U6. Combining the
data obtained from the previous study in which MEPCE
and Cdk9 were tagged (24) with the data obtained here by
TAP tagging LARP7 allowed us to construct an interac-
tion network for LARP7, MEPCE and P-TEFb
(Figure 1D). Note that arrows point from the tagged
protein to the protein discovered to interact. Many of the
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LARP7. Not surprisingly, LARP7 is tightly connected
to P-TEFb (cyclin T1 and Cdk9 subunits), its negative
regulatory factors (HEXIM1 and HEXIM2) and MEPCE
(Figure 1D). Together, our results indicate that LARP7
may be a part of the 7SK HEXIM MEPCE P-TEFb
snRNP. To facilitate further analysis of the endogenous
LARP7 protein, we developed a highly speciﬁc LARP7
antibody in sheep that detects a band near the predicted
molecular weight (69kDa) of LARP7 (Figure 1E).
LARP7 co-sediments withlarge formP-TEFb and7SK
To analyze the potential association of LARP7 and
MEPCE with P-TEFb, HEXIM1 and 7SK, glycerol
gradient sedimentation analysis of HeLa cell lysates was
carried out. Otherwise identical cultures were either mock-
treated or treated with 500nM Flavopiridol for 1h.
Flavopiridol is a potent P-TEFb inhibitor that leads to
inhibition of RNAPII transcription and to the release of
P-TEFb and HEXIM1 from the large 7SK containing
snRNP (37). As expected, in control cells most of the
Figure 1. LARP7 is associated with P-TEFb, HEXIM, MEPCE, 7SK snRNA and U6 snRNA. (A) Schematic comparison of La with LARP7 with
information obtained by querying NCBI’s Conserved Domain Database. La—La domain, RRM1—RNA recognition motif 1, RRM3— RNA
recognition motif 3. (B) SDS gel showing the composition of an aﬃnity-puriﬁed LARP7-TAP eluate. The tagged protein is indicated by an asterisk.
(C) Northern blots were performed on total RNA extracted from HEK 293 cells (T; 900ng) or RNA extracted from the LARP7-TAP eluate
(L; 60ng) and probed with RNA oligos speciﬁc for U2, U6 or 7SK snRNAs. (D) Network highlighting the interactions of LARP7 with various RNA
processing factors, P-TEFb (CCNT1/cyclin T1 and Cdk9 subunits), its negative regulatory factors (HEXIM1 and HEXIM2) and the 7SK snRNA
capping enzyme MEPCE. (E) Western blot of HeLa whole cell extract (WCE) or HeLa nuclear extract (NE) probed with the aﬃnity puriﬁed LARP7
antibody generated in sheep. Arrowhead—LARP7.
2222 Nucleic Acids Research, 2008, Vol. 36, No. 7P-TEFb (cyclin T1 and Cdk9) and about 20% of
HEXIM1 were found in fractions 9–11 that contain the
7SK snRNP with inactive P-TEFb (Figure 2A). The 7SK
capping enzyme, MEPCE, was previously found in a
complex containing P-TEFb, HEXIM1 and 7SK (24).
Here slightly less than half of MEPCE was found to
co-sediment with P-TEFb in control cells (Figure 2A) and
the rest exhibited a slower sedimentation (found toward
the top of the gradient). This observation is not surprising
since MEPCE was found associated predominantly with
U6 snRNA and could potentially be associated with other
small RNAs that it targets for capping (24,38). LARP7,
on the other hand, completely co-sedimented with
P-TEFb and HEXIM1 in the 7SK snRNP (Figure 2A).
Flavopiridol treatment led to the expected release of
P-TEFb and HEXIM1 from the 7SK snRNP and subse-
quent shift towards the top of the gradient (Figure 2B).
MEPCE sedimentation was unaﬀected. However, LARP7
shifted about one fraction down the gradient (Figure 2B).
To determine if this shift down the gradient was
consistent with LARP7 maintaining an association with
7SK after release of P-TEFb and HEXIM1, we extracted
RNA from each of the glycerol gradient fractions and
subjected them to northern analysis. In control cells, 7SK
appeared in fractions 8–14, peaking in fraction 9;
however, after Flavopiridol treatment, 7SK shifted down
the gradient and peaked in fraction 10 (Figure 2C). To be
sure that the shift in 7SK was not due to diﬀerences in the
sedimentation or fractionation of the two samples, we
visualized other RNAs with EtBr staining of the gel before
the transfer. The pattern of sedimentation of other RNAs
was identical between the two gradients, but as was found
by the northern analysis, the pattern of 7SK changed
(Figure 2D). These data strongly suggest that LARP7
remains in a stable complex with the 7SK snRNP even
after Flavopiridol treatment and the release of P-TEFb
and HEXIM1 from the snRNP. The shift down the
gradient is likely due to association of hnRNP proteins
(39–41).
LARP7 isastable component of the7SK snRNP
Results presented so far strongly suggest that LARP7
forms a complex with the large form of P-TEFb and
remains in complex with 7SK after P-TEFb release. To
determine if endogenous LARP7 is actually a component
of these complexes, we carried out a series of immuno-
precipitation experiments using an aﬃnity puriﬁed
LARP7 antibody. Glycerol gradient fractions 8–11,
which contain  80% of LARP7 (Figure 2A and B),
were pooled from either control or Flavopiridol-treated
cells and passed over beads that lacked antibody or had
LARP7 antibody covalently attached. Analysis by either
northern blot or EtBr staining of the RNA gel gave the
same result. About 90% of 7SK was retained on the beads
containing LARP7 antibody, but not on control beads
(Figure 3A). Here, because care was taken to avoid
ribonucleases, all the 7SK detected was intact. This
indicates that LARP7 interacts with full length 7SK and
not just the degradation products detected after the TAP
puriﬁcation earlier. Flavopiridol treatment of cells and the
subsequent release of P-TEFb and HEXIM did not
change the association of 7SK with LARP7 (Figure 3A).
Pulldown of 7SK from these samples was highly speciﬁc,
and did not aﬀect the binding of the other small RNAs
found in the gradient fractions (Figure 3A, ethidium
bromide). Immunoprecipitation of LARP7 also resulted in
the immunodepletion of HEXIM1 and Cdk9 from control
gradient samples, and as expected these two proteins were
absent from the samples from Flavopiridol-treated
cells (Figure 3A, western blot). Some, but not all, of the
Figure 2. LARP7 co-sediments with the 7SK snRNP before and after
P-TEFb and HEXIM release. (A) Glycerol gradient sedimentation
analysis of untreated HeLa cells. Western blotting was performed with
the indicated antibodies. (B) Gradient analysis of cells treated with
500nM Flavopiridol for 1h. (C) Northern blot of 7SK from gradient
samples used in A and B. (D) Ethidium bromide stain of the RNA gels
in C prior to northern transfer.
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treatment of cells with Flavopiridol caused less MEPCE to
be pulled down (Figure 3A, western blot).
To determine if LARP7 associates directly with 7SK,
we generated recombinant LARP7 in E. coli and used the
protein in an electrophoretic mobility shift assay (EMSA)
with radioactively labeled 7SK as the probe (Figure 3B).
As increasing amounts of LARP7 were added, two 7SK
mobility shifts were observed. The two RNPs could be due
to the binding of LARP7 to one or two molecules of 7SK
or one or two molecules of LARP7 binding to a single
molecule of 7SK. From these results we conclude that
LARP7 binds directly to 7SK.
To further examine the proteins associated with the
7SK snRNP before and after release of P-TEFb,
immunoprecipitations from whole cell extracts of control
cells or cells treated with another P-TEFb inhibitor, DRB,
were performed using LARP7, HEXIM1 and hnRNP A1
antibodies. Regardless of the presence of the large form of
P-TEFb, LARP7 was associated with a signiﬁcant fraction
of 7SK (Figure 3C). Immunoprecipitation of the 7SK
snRNP from control cells using a HEXIM1 antibody
veriﬁed that LARP7 is associated with this complex before
but not after release of P-TEFb (Figure 3C). Recent
research has shown that HEXIM and P-TEFb are
replaced by hnRNP proteins after release from the 7SK
snRNP (39,40). Here we conﬁrm that the association of
hnRNP A1 with 7SK increases after release, and show
that only after release does hnRNP A1 associate with
LARP7. Note that the immunoprecipitation with the
LARP7 antibody brought down only a small fraction (less
than 5%) of the hnRNP A1 protein which is more clearly
seen with a longer exposure (Figure 3C, bottom blot). The
low fraction bound to 7SK is expected since hnRNP A1 is
found in many other RNPs. Overall, these results
demonstrate that LARP7 is a stable component of the
7SK snRNP while HEXIM1, P-TEFb and hnRNP A1
are not.
Knockdown of LARP7 decreasesthe steady-state level
of 7SKwhile increasing free P-TEFb and enhancing
Tat-mediated transcription
Given the well-established role of the La protein in the
protection of RNAPIII transcripts from 30 exonucleolytic
degradation (34), we asked whether knockdown of
LARP7 expression by siRNA would have a negative
eﬀect on 7SK snRNA steady-state levels in human cells.
Figure 4A shows that reducing the expression of LARP7
by about 70% in vivo (Figure 4A) caused a decrease in the
steady-state level of 7SK (Figure 4B). LARP7 knockdown
had no eﬀect on U2 or U6 snRNA levels (Figure 4B).
This result indicates that LARP7 stabilizes the 7SK
snRNA in human cells.
Since knockdown of LARP7 resulted in reduced
stability of 7SK, we next determined the eﬀect of
LARP7 knockdown on the ratio of the forms of
P-TEFb and on P-TEFb activity. Glycerol gradient
analysis was carried out on control cells or cells treated
with either LARP7 or MEPCE siRNA. siRNA treatment
resulted in a 70% reduction of both LARP7 and MEPCE
(Figure 4C and D). Knockdown of either protein resulted
in a small, but signiﬁcant increase in the amount of free
P-TEFb; however, the eﬀect of MEPCE knockdown was
less dramatic (Figure 4E). Because the release of P-TEFb
is a highly regulated process, we speculated that the
increase in free P-TEFb mediated by the loss of LARP7
and MEPCE and subsequent loss of 7SK would aﬀect
transcription. LARP7 and MEPCE siRNAs were intro-
duced into human HEK 293 cells, followed by the trans-
ient transfection of an HIV-1 LTR-luciferase reporter
construct in the presence of the HIV-1 transactivator,
Tat. As shown in Figure 4F, knockdown of LARP7
caused a consistent  2-fold increase in Tat-mediated
transactivation of the HIV-1 LTR. Knockdown of
MEPCE had little or no eﬀect either alone or in
combination with knockdown of LARP7. Essentially the
same results were observed in TZM-bl cells, a stable
HeLa-derived cell line containing an integrated luciferase
Figure 3. Immunoprecipitation of LARP7 conﬁrms that it is a stable
component of the 7SK snRNP. (A) Glycerol gradient fractions were
pooled and subjected to LARP7 immunoprecipitation as described in
the text. Nucleic acid and protein bound to the beads were either Trizol
extracted or released in SDS loading buﬀer and analyzed by northern
blotting, ethidium bromide staining and western blotting with the
indicated antibodies. (B) Autoradiograph from the EMSA of E. coli
expressed recombinant LARP7 bound to radioactively labeled 7SK.
(C) Co-immunoprecipitation of the 7SK snRNP with HEXIM1 (HEX),
hnRNP A1 (A1) and LARP7 antibodies before and after DRB
treatment. Samples were then subjected to northern blotting for 7SK
and western blotting with the indicated antibodies. Two exposures of
the hnRNP A1 western blot are shown.
2224 Nucleic Acids Research, 2008, Vol. 36, No. 7reporter gene driven by the HIV-1 LTR (data not shown).
The relatively weak enhancement of Tat-mediated trans-
activation was most likely due to the 25–50% eﬃciency of
LARP7 knockdown in treated cells (data not shown).
Of note, these results compare well with those obtained in
an earlier study of the eﬀect HEXIM1 knockdown on
transcription from the HIV-1 promoter, which also led to
a  2-fold increase (12). Together, these data provide
evidence that LARP7 plays an important role in stabiliz-
ing and maintaining the 7SK snRNP. Knockdown of
LARP7 led to both a reduction in 7SK and to an increase
in active P-TEFb.
Knockdownof 7SK disrupts thelarge form of P-TEFb
To determine if the level of 7SK could directly impact the
amount of free P-TEFb, siRNA directed against 7SK was
used to knock down the snRNA. Previously, 7SK siRNA,
but not a non-speciﬁc siRNA, was shown to speciﬁcally
reduce 7SK even though it is a nuclear RNA (42). Total
RNA was isolated 6, 12, 24, 48 or 72h post-transfection
from cells treated with siRNA or Lipofectamine 2000
alone. Northern blotting was performed to determine the
extent of 7SK knockdown. Knockdown was rapid and
persistent, with 7SK levels in siRNA-treated cells reduced
to 21% of control cells at 6h and 16% at 72h (Figure 5A).
The eﬀect of knockdown of 7SK on the forms of P-TEFb
was then examined by glycerol gradient sedimentation
analysis of cell lysates made 48h after mock transfection
or transfection with 7SK siRNA. In the control cells, the
vast majority of P-TEFb was found in the large form, with
a small amount in the free form (Figure 5B, Control). The
ratio of the free and large forms of P-TEFb was
dramatically shifted by 7SK knockdown, with very little
P-TEFb remaining in the large form (Figure 5B, 7SK
siRNA). We conclude that reduction in the amount of
7SK in cells leads to the release of P-TEFb from the large
form and is similar to the eﬀect seen after LARP7
knockdown (Figure 4E) except that when 7SK siRNA is
used the reduction in 7SK is much more rapid. However,
at the 48h time point analyzed the absolute signals for
cyclin T1 and Cdk9 in 7SK siRNA-treated cells were
reduced compared to control cells (Figure 5B).
To explore the possibility that 7SK siRNA treatment
aﬀected the overall level of P-TEFb, cells were transfected
with siRNA or mock-transfected, lysed with SDS after
64h, and the lysates were analyzed by northern and
western blotting. Northern blotting for 7SK conﬁrmed
that it was reduced to  20% of control cells (Figure 5C).
Knockdown of 7SK caused a reduction in both Cdk9 and
cyclin T1 to 30% (Figure 5C), indicating that the absolute
amount of P-TEFb is dependent on 7SK levels. Evidently,
the prolonged release of active P-TEFb from the disin-
tegrating large form triggers the reduction of P-TEFb.
Additionally, reduction of free P-TEFb could be part
of the explanation for why only low levels of released
P-TEFb were detected 72h after the LARP7 siRNA
treatment of cells (Figure 4E).
Finally, to determine if LARP7 knockdown had a
similar eﬀect as 7SK knockdown on total P-TEFb levels,
HeLa cells were mock-transfected or transfected with 10,
Figure 4. Knockdown of LARP7 decreases 7SK levels, increases free
P-TEFb, and enhances Tat transactivation. (A) LARP7 knockdown
(72h post-transfection) was monitored by western blotting in extracts
from HEK 293 cells mock-transfected or transfected with control or
LARP7 siRNA (tubulin was used as a loading control). (B) 7SK
steady-state levels were assessed by RNA blotting using total RNA
extracted from HEK 293 cells mock-transfected or transfected with
control or LARP7 siRNA (48 and 72h post-transfection) and probed
with RNA oligonucleotides that speciﬁcally detect 7SK, U6 or U2
snRNAs. (C) Knockdown of LARP7 in HeLa cell glycerol gradient
input or the leftover nuclear pellet 72h post-transfection was
determined by western blot and comparison with an actin loading
control. (D) Same conditions as C, except the siRNA used targeted
MEPCE. (E) Glycerol gradient analysis of the large form of P-TEFb
after siRNA knockdown of LARP7 and MEPCE using the Cdk9
antibody. (F) HEK 293 cells were mock-transfected or transfected twice
with control, MEPCE, LARP7 or double (MEPCE and LARP7)
siRNAs and an HIV-1 LTR-luciferase reporter construct. A Tat-
expressing plasmid was co-transfected where indicated. Luciferase
activity was measured 24h after transfection. Results are presented as
fold activation relative to transfections in the absence of the Tat
expression plasmid. N=3.
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knockdown resulted in a signiﬁcant decrease in both Cdk9
and cyclin T1 levels, paralleling the 7SK results, while
HEXIM1 was unchanged (Figure 5D). HEXIM1 levels
likely remained the same due to the fact that HEXIM1
in the large form is a small fraction of the total
HEXIM1 (Figure 2A). Loss of the 7SK snRNP by
either 7SK or LARP7 knockdown underscores the
importance of 7SK stability in maintaining proper control
over P-TEFb.
DISCUSSION
We have examined the association of LARP7 with 7SK,
P-TEFb, HEXIM1, MEPCE and hnRNP A1. Although
the study began with a TAP-tagged LARP7 pulldown, all
other experiments involved analysis of endogenous
LARP7. Glycerol gradient sedimentation and immuno-
precipitation experiments were used to compare the 7SK
snRNP in control cells with the snRNP in cells treated
with P-TEFb inhibitors or siRNAs. Our study demon-
strated that LARP7 is a stable component of two major
7SK snRNPs that are present before and after the release
of P-TEFb (Figure 6). Treatment of cells with P-TEFb
inhibitors caused the P-TEFb HEXIM1 MEPCE 
LARP7 7SK complex to be converted into an
hnRNPA1 LARP7 7SK complex. Only a small (substoi-
ciometric) amount of MEPCE was found to associate with
7SK and LARP7 after release of P-TEFb. Knockdown of
LARP7 led to a reduction of 7SK, the release of P-TEFb
from the large form and the activation of transcription
from the HIV LTR. Additionally, reduction of 7SK by
direct siRNA knockdown or by knockdown of LARP7
caused a time-dependent reduction in the total amount of
P-TEFb. This suggests that there is a cellular mechanism
that regulates the level of free P-TEFb when it is not
inhibited by the 7SK snRNP. Based on bioinformatic
analysis LARP7 is the most closely related family member
to the founding protein, La. The similarities in the domain
structure of La and LARP7 suggest that they may have
similar properties. La has been found in association with
many nascent RNAPIII transcripts including 7SK
(40,41,43). We propose that LARP7 replaces La during
7SK snRNP maturation. This would explain our ﬁnding
that  90% of the 7SK snRNP was immunoprecipitated
with LARP7 antibodies (Figure 3). This represents a
diﬀerence between LARP7 and La in that La is not
present in the ﬁnal mature form of most snRNPs (44–47).
The results presented here show that LARP7 protects 7SK
from degradation similarly to La’s role in protecting other
RNPs (34). It is possible that this is accomplished through
the binding of the La domain and RRM1 of LARP7 to
Figure 5. Direct knockdown of 7SK disrupts the large form of P-TEFb and decreases total P-TEFb. (A) HeLa cells were mock-treated or treated
with 7SK siRNA for the indicated periods of time. One control and two independent siRNA treatments are shown for each time point. C-Control,
R-siRNA-treated. (B) HeLa cells were mock-treated or treated with 7SK siRNA for 48h, subjected to glycerol gradient sedimentation, and analyzed
by western blot using the indicated antibodies. (C) HeLa cells were mock-treated or treated with 7SK siRNA for 64h. Quantitative northern blotting
for 7SK and western blotting for cyclin T1 and Cdk9 were performed. C-Control, R-siRNA-treated. (D) HeLa cells were treated with the indicated
amount of LARP7 siRNA for 48h, lysed in SDS loading buﬀer and western blotted with the indicated antibodies. Non-speciﬁc bands (ns) are
provided as a loading control.
Figure 6. Model of the 7SK snRNP before and after release of
P-TEFb. Prior to treatment with P-TEFb inhibitors or cellular stress,
the 7SK snRNP contains P-TEFb, a HEXIM dimer, MEPCE, LARP7
and 7SK. Following release, the 7SK snRNP is composed of, LARP7,
7SK and hnRNP proteins.
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role in RNA protection, La has been implicated in
nuclear localization and nucleolar traﬃcking of RNAs
such as U6 and 7SL (36). Binding of LARP7 to 7SK may
partially explain why 7SK is predominantly nuclear (48).
Interestingly, recent analysis of the crystal structure of La
shows that the La domain contains hallmarks of a DNA
binding protein and the surfaces that were assumed to
be involved in RNA binding are actually free (33). In
conjunction with this ﬁnding, La has been shown to
localize to RNAPIII promoters (49). It would be
intriguing if LARP7 had a similar localization to DNA.
If so then it could either be used to target inactive P-TEFb
to positions on the chromatin for local release to enhance
RNAPII transcription, or position 7SK on chromatin for
local regulated inhibition of P-TEFb.
Binding of La to its RNA targets is a regulated process
that is dependent on the 50 and 30 ends of the RNA and the
phosphorylation state of La. A 50-monomethyl-guanosine
capping of U6 and B2 RNA has been shown to reduce
the aﬃnity of La for these RNAs while adenylation of
these transcripts completely releases La (50,51). The recent
discovery of MEPCE, which monomethylates U6 and
7SK on their 50 termini may provide a mechanism for
7SK release from La and the subsequent association of
LARP7. However, the status of the 50 end of 7SK bound
by LARP7, as well as, the methylation preference of
LARP7 has yet to be determined. Alternatively, it is
possible that 50 end capping of 7SK might aﬀect the way
that LARP7 and 7SK interact and that could impact the
association or dissociation of P-TEFb and HEXIM1.
It is also possible that modiﬁcation of the 30 end of 7SK
could be used for regulation of the protein composition of
the 7SK snRNP.
Approximately 70% of 7SK is post-transcriptionally
adenylated on the 30 end (52) and this modiﬁcation has
been shown to aﬀect La binding to other RNAPIII
snRNAs. This modiﬁcation may provide a mechanism for
release of 7SK from La or release of P-TEFb from the
LARP7 7SK snRNP. Release of P-TEFb from the
LARP7 7SK snRNP could be accomplished by altering
the association of LARP7 with 7SK in such a way that the
secondary structure of the RNA is aﬀected and prevents
HEXIM and P-TEFb binding. It is possible that the 25%
of 7SK that is associated with P-TEFb (Figure 3A,
Northern and 3B, 7SK) might be the fraction of 7SK,
 30%, that is not adenylated. Phosphorylation of Ser366
of La has been shown to reduce 50 end binding (53)
providing another feasible regulatory mechanism.
Results from the 7SK and LARP7 knockdown experi-
ments performed here provide evidence for the coordina-
tion of two cellular mechanisms regulating the level of free
P-TEFb. When the level of free P-TEFb was increased
by disruption of the large form during siRNA-mediated
knockdown of LARP7, an increase in P-TEFb activity
was observed. After several days of LARP7 or 7SK
siRNA treatment less total P-TEFb was found. This is
consistent with an initial increase in P-TEFb activity as
the large form is disrupted followed by a slower cellular
compensation that leads to reduction in the total amount
of P-TEFb protein by increasing turnover or decreasing
synthesis of Cdk9 and cyclin T1. The mechanism for the
reduction of excess free P-TEFb is likely to be proteosome
mediated decay because when P-TEFb subunits were
overexpressed most of the P-TEFb was quickly ubiquity-
lated and degraded by the proteasome (54,55).
Degradation of the free P-TEFb would explain why we
found only a slight increase in free P-TEFb after LARP7
knockdown. The idea that the amount of free P-TEFb
arises from a balance between release from the large form
and degradation of the free form is supported by the
ﬁnding that knockdown of either Cdk9 or cyclin T1 results
in a reduction of the total amount of P-TEFb in the cell
without grossly aﬀecting transcription of a reporter gene
or cell viability (56). In the future, it is important to
determine how these mechanisms are used to obtain the
selective P-TEFb function required for control of tran-
scription during diﬀerentiation and development.
Mechanisms regulating the balance of free versus
inactive P-TEFb have been previously characterized.
Knockdown of HEXIM1 was shown to have no eﬀect
on the absolute levels of P-TEFb or the amount of
P-TEFb in the large form because HEXIM1 was
functionally replaced by HEXIM2 (14,15). Two studies
have shown that long-term treatment of cells with HMBA,
caused an initial increase in free active P-TEFb, but
ultimately resulted in a shift in the equilibrium back to the
large inactive form (19,57). Together these studies provide
support for a variety of cellular mechanisms that maintain
the P-TEFb equilibrium in cells.
Comparative genomic analysis shows that LARP7 is
closely related to the Drosophila melanogaster protein
multi sex combs (mxc). The domain structure of mxc is
very similar to that of LARP7 and contains a La motif
and two RRMs. In ﬂies, mxc is a member of the Polycomb
group (PcG) of genes which regulate gene expression
during diﬀerentiation and development (58). Mxc appears
to function as a tumor suppressor because mutations were
shown to result in uncontrolled malignant growth (59).
Additionally, there is evidence that LARP7, studied under
the alias DKFZP564K112, is a marker of gastric cancer as
determined by microsatellite instabilotyping (60). Genetic
studies in ﬂies show that complete loss of mxc results in
cell death after a few divisions while hypomorphic
expression results in abnormalities during development
(61). Mxc is also implicated in Drosophila hematopoiesis
by controlling plasmatocyte proliferation and diﬀerentia-
tion (62). It would be interesting to see if the phenotypes
observed in ﬂies are related to an interaction between ﬂy
P-TEFb and its LARP7 homolog mxc. With these results
in mind, it is important that we determine how LARP7
regulates P-TEFb function during cell diﬀerentiation,
development and cancer progression.
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